Marker Therapeutics
MRKR
48 hedge funds and large institutions have $7.36M invested in Marker Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 6 closing their positions.
1.44% less ownership
Funds ownership: 28.08% → 26.64% (-1.4%)
2% less funds holding
Funds holding: 49 → 48 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
28% less capital invested
Capital invested by funds: $10.3M → $7.36M (-$2.92M)
73% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$48K |
| 2 |
MAA
Matrix Asset Advisors
White Plains,
New York
|
+$33.3K |
| 3 |
Jane Street
New York
|
+$21.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.42K |
| 5 |
VF
Virtu Financial
New York
|
+$5.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$150K |
| 2 |
Renaissance Technologies
New York
|
-$105K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$57.1K |
| 4 |
BlackRock
New York
|
-$47K |
| 5 |
Millennium Management
New York
|
-$46.7K |
MRKR Hedge Fund Activity: Q2 2022 in Review
48 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2022, worth a combined $7.36M — down 28% from $10.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MRKR and 5 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $48K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $150K sold.
- 48 institutional investors held Marker Therapeutics (MRKR) as of Q2 2022, down from 49 in Q1 2022.
- Funds reported $7.36M of Marker Therapeutics stock for Q2 2022, down 28% quarter-over-quarter.
- 5 funds opened new Marker Therapeutics positions in Q2 2022 and 6 closed out, a net change of -1 holder.
- The largest Marker Therapeutics buyer in Q2 2022 was Citadel Advisors, an estimated $48K added.
- The largest Marker Therapeutics seller in Q2 2022 was Two Sigma Advisers, an estimated $150K sold.
Based on aggregated 13F filings for Q2 2022.